Literature DB >> 24583636

Vaccine immunity against fungal infections.

Som G Nanjappa1, Bruce S Klein2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24583636      PMCID： PMC4037332          DOI： 10.1016/j.coi.2014.01.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


× No keyword cloud information.
  77 in total

1.  CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis.

Authors:  K Quimby; E A Lilly; M Zacharek; K McNulty; J E Leigh; J E Vazquez; P L Fidel
Journal:  Oral Dis       Date:  2011-09-30       Impact factor: 3.511

2.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

3.  Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.

Authors:  Stephen P Saville; Anna L Lazzell; Ashok K Chaturvedi; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

4.  A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.

Authors:  Eric J Tarcha; Venkatesha Basrur; Chiung-Yu Hung; Malcolm J Gardner; Garry T Cole
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

6.  Priming of memory but not effector CD8 T cells by a killed bacterial vaccine.

Authors:  G Lauvau; S Vijh; P Kong; T Horng; K Kerksiek; N Serbina; R A Tuma; E G Pamer
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

Review 7.  Adaptive immunity to fungi.

Authors:  Marcel Wüthrich; George S Deepe; Bruce Klein
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

8.  Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination.

Authors:  Silvia Bozza; Cecile Clavaud; Gloria Giovannini; Thierry Fontaine; Anne Beauvais; Jacqueline Sarfati; Carmen D'Angelo; Katia Perruccio; Pierluigi Bonifazi; Silvia Zagarella; Silvia Moretti; Francesco Bistoni; Jean-Paul Latgé; Luigina Romani
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

9.  Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans.

Authors:  S M Levitz; M P Dupont; E H Smail
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis).

Authors:  Suzanne M Johnson; Nicholas W Lerche; Demosthenes Pappagianis; Joann L Yee; John N Galgiani; Richard F Hector
Journal:  Ann N Y Acad Sci       Date:  2007-03-08       Impact factor: 5.691
View more
  16 in total

1.  CBLB Constrains Inactivated Vaccine-Induced CD8+ T Cell Responses and Immunity against Lethal Fungal Pneumonia.

Authors:  Som G Nanjappa; Srinivasu Mudalagiriyappa; J Scott Fites; M Suresh; Bruce S Klein
Journal:  J Immunol       Date:  2018-07-27       Impact factor: 5.422

2.  Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.

Authors:  Yanyan Huai; Shuai Dong; Ye Zhu; Xin Li; Binrui Cao; Xiang Gao; Mingying Yang; Li Wang; Chuanbin Mao
Journal:  Adv Healthc Mater       Date:  2016-02-18       Impact factor: 9.933

Review 3.  Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.

Authors:  Elizabeth J Polvi; Xinliu Li; Teresa R O'Meara; Michelle D Leach; Leah E Cowen
Journal:  Cell Mol Life Sci       Date:  2015-02-21       Impact factor: 9.261

Review 4.  Vaccinations for Neuroinfectious Disease: A Global Health Priority.

Authors:  Emily C Leibovitch; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

5.  Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.

Authors:  Kristopher K Short; Shannon M Miller; Lois Walsh; Van Cybulski; Hélène Bazin; Jay T Evans; David Burkhart
Journal:  J Control Release       Date:  2019-10-22       Impact factor: 9.776

6.  Vaccine-Induced Protection in Two Murine Models of Invasive Pulmonary Aspergillosis.

Authors:  Emily Rayens; Whitney Rabacal; S Earl Kang; Brandi N Celia; Michelle Momany; Karen A Norris
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

Review 7.  Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?

Authors:  Karl Kuchler; Sabrina Jenull; Raju Shivarathri; Neeraj Chauhan
Journal:  PLoS Pathog       Date:  2016-11-10       Impact factor: 6.823

Review 8.  Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.

Authors:  Pappanaicken R Kumaresan; Thiago Aparecido da Silva; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

9.  Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development.

Authors:  Antonella Rella; Visesato Mor; Amir M Farnoud; Ashutosh Singh; Achraf A Shamseddine; Elitza Ivanova; Nicholas Carpino; Maria T Montagna; Chiara Luberto; Maurizio Del Poeta
Journal:  Front Microbiol       Date:  2015-08-11       Impact factor: 5.640

Review 10.  New insights on the development of fungal vaccines: from immunity to recent challenges.

Authors:  Natasha P Medici; Maurizio Del Poeta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11-24       Impact factor: 2.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.